Myriad Genetics Inc (MYGN) · Nov 4, 2026 · Earnings

Myriad Genetics earnings beat estimates as Prenatal sale reshapes growth

Beat — Adjusted EPS $(0.11) vs approximately $(0.17) consensus

Myriad Genetics earnings beat Q3 estimates and lifted the 2026 revenue midpoint, but core growth remains modest and profitability is still negative.

Myriad is repositioning around its Cancer Care Continuum and Mental Health businesses after deciding to sell Prenatal Health, following a Q2 reset driven by payer friction, weaker prenatal volumes, and more conservative assumptions for the second half of 2026.

The quarter beat a lowered bar. Revenue of $202.7 million exceeded the published consensus of approximately $191.3 million, while adjusted EPS of $(0.11) was better than the roughly $(0.17) consensus. Revenue also rose 6% sequentially, although it was still down 1% year over year.

FigureReportedPrior yearConsensus / prior guide
Revenue (Financial Highlights)$202.7M$205.7M~$191.3M
Adjusted EPS (Adjusted Net Income table)$(0.11)—~$(0.17)
CCC + Mental Health revenue (Product revenues)$163.4M$161.2M—
Adjusted EBITDA (Adjusted EBITDA table)$(5.3)M$10.3M—
FY2026 revenue guidance (Financial Guidance)$780–$790M—Prior midpoint: $780M

The continuing business is growing, but only barely at the revenue line. Cancer Care Continuum and Mental Health revenue increased 1% year over year, while their combined test volume rose 3%; better revenue per test, including early progress in payer and revenue-cycle initiatives, is doing more work than demand growth. Prenatal Health revenue fell 12% and volume fell 11%, reinforcing why the divestiture was already part of the standing story. 〔0〕

The profitability signal is weaker than the headline beat. Adjusted EBITDA swung to a $5.3 million loss from a $10.3 million profit last year, adjusted operating expenses rose $9.9 million, and nine-month adjusted free cash flow remained negative at $29.2 million. The quarter produced only $1.6 million of adjusted free cash flow, while reported operating cash flow was negative $6.5 million.

Guidance moved modestly higher, not decisively. The full-year revenue midpoint rose to $785 million from $780 million, reflecting the quarter’s upside but also the pending Prenatal Health sale. That is a small improvement rather than evidence that the underlying business has entered a high-growth phase; the company still guides to a 66%–67% adjusted gross margin and does not provide adjusted EBITDA guidance. 〔1〕

The Prenatal sale remains the larger strategic change, but it is not new in this filing. Myriad had already announced the planned $210 million cash sale to Labcorp on October 19, 2026, so this release mainly quantifies the business being exited and frames the proceeds as future balance-sheet support. Completion remains subject to customary conditions and is expected by early 2027.

Bottom line: Myriad delivered a real earnings and revenue beat and nudged guidance higher, but the underlying story is still mixed: its retained businesses are growing modestly while adjusted profitability and cash generation remain strained. The quarter improves execution credibility, but does not yet rewrite the turnaround story.

What to watch next

Prenatal Health sale closing, expected by early 2027

Original filing on SEC EDGAR

More Myriad Genetics Inc news

Myriad Genetics earnings beat estimates as Prenatal sale reshapes growth | MYGN Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.